De-Risking Preclinical Development: The Emergence of the Contract Vivarium
Recent studies on the success rates of drug development in the biopharmaceutical industry reported that 50% of all drugs brought to clinical trials fail because independent labs have an inability to reproduce efficacy as demonstrated in preclinical trials. This ‘reproducibility crisis’ has cost the industry nearly $28 billion in failed clinical trials.
In response, AstraZeneca implemented a “5Rs Framework” for its preclinical drug discovery and development to boost productivity and shareholder confidence. It’s working.
But early-to mid-stage biotechs rely on incremental funding to scale their preclinical stages and don’t typically have big pharma facilities or infrastructure. They often have only one chance to bring their drug to clinical trials, and they’re most likely risking it all: funding, safety, efficacy validation, maybe even the company itself.
How can emerging biotechs take a page from AstraZeneca’s “5Rs Framework” and increase the success rates of their preclinical trials, minimize the risk of failed clinical trials and control their science?
We propose a 6th ‘R’: Right Control, with the contract vivarium model.
In this paper you'll learn:
How you can apply AstraZeneca’s “5Rs Framework” to your biotech’s preclinical research with a contract vivarium (CV) and minimize clinical failure rates while staying in control of your science
How to ensure a greater rate of reproducibility in later stage trials with the contract vivarium model and avoid the adverse effects of outsourcing your science
How contract vivariums minimize disproportionate spend in early-stage preclinical studies
How CVs allow research teams to focus on truth-seeking and good science by keeping their studies in-house rather than outsourcing to a Contract Research Organization (CRO)
Read the full paper and learn how a full service contract vivarium can support your preclinical research.